摘要
目的:对普拉克索联合左旋多巴治疗帕金森的效果进行评价。方法:将医院确诊收治的78例帕金森病患者纳入研究,按照随机数字原则分为对照组37例,观察组41例。对照组单纯应用左旋多巴治疗,观察组在对照组基础上联合普拉克索治疗,对比两组治疗后效果。结果:观察组治疗后UPDRS评分、氧化应激反应指标均优于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论:普拉克索联合左旋多巴应用于帕金森病治疗中,能够显著改善患者的症状评分、应激反应,且联合用药安全可靠。
Objective: To evaluate the efficacy of Pramipexole combined with Levodopa in the treatment of Parkinson disease. Method: A total of 78 patients with Parkinson disease diagnosed and treated in the hospital were included in the study. According to the principle of random number, patients were divided into the control group (37 cases) and the observation group (41 cases). The control group was treated with Levodopa alone, while the observation group was treated with Pramipexole on the basis of the control group. The therapeutic effects of the two groups were compared. Result: After treatment, the UPDRS scores and indexes of oxidative stress response in the observation group were significantly better than those of the control group, and the differences were statistically significant (P<0.05). The incidence of adverse reactions was compared between the two groups, and the difference was not statistically significant (P>0.05). Conclusion: Pramipexole combined with Levodopa in the treatment of Parkinson disease can significantly improve the patients’ symptom score and stress response, and the combination of drugs is safe and reliable.
作者
刘兴洲
LIU Xingzhou(Jingzhou Third People’s Hospital, Jingzhou 434001, China)
出处
《中外医学研究》
2019年第28期52-54,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
